Acumen raises $20m Series A for Alzheimer's antibody

Acumen Pharmaceuticals completed the first closing a $20 million Series A funding round, which will be used to demonstrate proof of concept for the monoclonal antibody ACU-193 in the treatment of Alzheimer's disease by 2016.